Pharmacodynamic assessment of cefprozil against Streptococcus pneumoniae:: Implications for breakpoint determinations

Cefprozil, an oral semissynthetic cephalosporin, is commonly utilized in the treatment of respiratory-tract infections in children. While this agent has provided acceptable clinical success over a number of years, this study was undertaken to better define its pharmacodynamic profile against Streptococcus pneumoniae. Nineteen clinical isolates of S. pneumoniae were utilized in the neutropenic murine thigh infection model. To simulate the pharmacokinetic profile of cefprozil in children, the renal function of mice was impaired with uranyl nitrate, and a commercially available cefprozil suspension (6 mg/kg of body weight) was administered orally every 12 h, Mice were infected with 10(6) to 10(7) CFU per thigh, and therapy was initiated 2 h later. At 0 and 24 h postinfection, thighs were harvested to determine bacterial density. Survival was assessed during 96 h of therapy. The magnitude of bacterial kill ranged from 0.5 to 4.4 log(10) CFU per thigh over 24 h, and the extent of microbial eradication was dependent on the MIC. Killing of more than 2.6 log(10) CFU per thigh was observed with MICs of less than or equal to 3 mu g/ml, while either minimal killing or growth was detected with MICs of greater than or equal to 4 mu g/ml. Mortality in untreated control animals was 100%. Animals infected with strains for which the MICs were less than or equal to 2 mu g/ml survived the infection, whereas MICs exceeding 2 mu g/ml resulted in substantial mortality. These studies demonstrate the effectiveness of cefprozil against isolates of the pneumococcus for which the MICs are less than or equal to 2 mu g/ml using a drug exposure typically observed in children. These data support a susceptibility breakpoint of less than or equal to 2 mu g/ml for cefprozil.